



Creating a better future for nano-rare


What is n-Lorem?

n-Lorem is a non-profit committed to discovering and providing experimental treatments, for free, for life, to the most isolated and desperate patients: those who have genetic diseases that affect only one person or, at most, 30 patients worldwide.

We refer to these patients as having nano-rare mutations and most are truly an n of one.

n-Lorem was founded in January 2020. To date, n-Lorem has received over 330 applications for treatment with more than 160 nano-rare patients approved. That means greater than 160 patients and their families have hope. We receive applications daily and carefully select patients whom we think can benefit the most because, as you can imagine, this is expensive, and we rely solely on the kindness of donors to complete this mission.

hope



Who can we help?

Our nano-rare patients are infants, children, teenagers, young adults, middle-aged adults and senior adults. Patients can have nano-rare disorders with involvement in the central nervous system, the kidney, the liver, or eye. Nano-rare patients are often the only one in the world with their unique gene mutation, but this does not mean they should be left behind.

Most of these patients progress and die without ever achieving a diagnosis. Those that receive a diagnosis learn they have a unique mutation and, in very next breath, learn that there is no treatment and it is unlikely that there will be. This is where n-Lorem comes in. We do the impossible. We provide immediate hope and near-term opportunities for free lifetime treatment.



Doing the impossible

The reason we can do the impossible is the efficiency and versatility of our technology, antisense oligonucleotide (ASO) drug discovery. We bring more than three decades of leadership in creating and advancing ASO technology and, as such, we understand every aspect of the technology. This level of understanding is key to discovering and developing optimized experimental ASO medicines for our nano-rare patients.

A non-profit approach is the only way to treat nano-rare

Any commercial scale approach would require that nano-rare patients be charged millions of dollars. We think that our industry can and must do better than that. Armed with ASO technology, we can and are.

join us

We hope that you join us on this journey to discover, develop and provide individualized ASO medicines for free, for life, to nano-rare patients.

Contact:

Amy Williford, Ph.D.

*Exec. Director of Communications
and Donor Relations*

9410 Carroll Park Dr.
San Diego, CA 92121
(760) 378-8005
amy.williford@nlorem.org